Stocks and Investing Stocks and Investing
Mon, July 17, 2017
Fri, July 14, 2017
Thu, July 13, 2017
Wed, July 12, 2017
Tue, July 11, 2017
Mon, July 10, 2017
Fri, July 7, 2017
Thu, July 6, 2017
Wed, July 5, 2017
Mon, July 3, 2017
Fri, June 30, 2017
Thu, June 29, 2017
Wed, June 28, 2017
Tue, June 27, 2017
Mon, June 26, 2017
Fri, June 23, 2017
Thu, June 22, 2017
Wed, June 21, 2017
Tue, June 20, 2017
Mon, June 19, 2017
Fri, June 16, 2017
Thu, June 15, 2017
Wed, June 14, 2017
Tue, June 13, 2017
Mon, June 12, 2017
Fri, June 9, 2017
Thu, June 8, 2017
Wed, June 7, 2017
Tue, June 6, 2017
Mon, June 5, 2017
Fri, June 2, 2017
Thu, June 1, 2017
Wed, May 31, 2017

Andrew Peters Initiated (BIIB) at Strong Buy and Held Target at $315 on, Jun 23rd, 2017


//stocks-investing.news-articles.net/content/201 .. buy-and-held-target-at-315-on-jun-23rd-2017.html
Published in Stocks and Investing on Friday, October 25th 2024 at 21:26 GMT by   Print publication without navigation


Andrew Peters of Deutsche Bank, Initiated "Biogen Inc." (BIIB) at Strong Buy and Held Target at $315 on, Jun 23rd, 2017.

Andrew has made no other calls on BIIB in the last 4 months.



There are 3 other peers that have a rating on BIIB. Out of the 3 peers that are also analyzing BIIB, all agree with Andrew's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Carter Gould of "UBS" Upgraded from Strong Sell to Hold on, Monday, June 19th, 2017
  • Geoffrey Porges of "Leerink Swann" Downgraded from Buy to Hold on, Thursday, March 16th, 2017
  • Matthew Harrison of "Morgan Stanley" Downgraded from Buy to Hold and Decreased Target to $305 on, Thursday, March 16th, 2017